Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

62.28USD
19 Jan 2018
Change (% chg)

$0.45 (+0.73%)
Prev Close
$61.83
Open
$62.16
Day's High
$62.42
Day's Low
$61.57
Volume
2,305,875
Avg. Vol
1,558,008
52-wk High
$66.09
52-wk Low
$46.01

Select another date:

Mon, Jan 8 2018

BRIEF-Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb

* FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME

Bristol-Myers sees $3 billion tax hit in fourth quarter 2017

Bristol-Myers Squibb Co will record a $3 billion charge in the fourth quarter of 2017 as a result of the U.S. tax reform law passed last month, the drugmaker said in a regulatory filing on Friday.

Bristol-Myers sees $3 billion tax hit in fourth quarter 2017

Jan 5 Bristol-Myers Squibb Co will record a $3 billion charge in the fourth quarter of 2017 as a result of the U.S. tax reform law passed last month, the drugmaker said in a regulatory filing on Friday.

BRIEF-Bristol-Myers Estimates Tax Reform To Result In Additional Net Tax Expense Of About $3 Bln In Q4

* BRISTOL-MYERS SQUIBB - ESTIMATES THE IMPACT OF U.S. TAX REFORM TO RESULT IN ADDITIONAL NET TAX EXPENSE OF ABOUT $3 BILLION IN THE FOURTH QUARTER OF 2017‍​

BRIEF-Bristol-Myers Squibb Receives FDA Approval For Opdivo As Treatment For Patients With A Type Of Skin Cancer

* BRISTOL-MYERS SQUIBB RECEIVES FDA APPROVAL FOR OPDIVO (NIVOLUMAB) AS ADJUVANT THERAPY IN PATIENTS WITH COMPLETELY RESECTED MELANOMA WITH LYMPH NODE INVOLVEMENT OR METASTATIC DISEASE Source text for Eikon: Further company coverage:

BRIEF-Taris And Bristol-Myers Squibb Announce Clinical Trial Collaboration

* TARIS AND BRISTOL-MYERS SQUIBB ANNOUNCE CLINICAL TRIAL COLLABORATION

BRIEF-Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Yervoy (ipilimumab)

* BRISTOL-MYERS SQUIBB RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF YERVOY (IPILIMUMAB) FOR THE TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH UNRESECTABLE OR METASTATIC MELANOMA

BRIEF-Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists

* Says it entered into license agreement with Bristol-Myers Squibb Company (BMS)for Prostaglandin E2 receptor antagonists relating to Immuno-Oncology programs

BRIEF-Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment

* BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT

BRIEF-U.S. FDA Accepts Bristol-Myers Squibb’S Application For Opdivo (Nivolumab) Plus Yervoy (Ipilimumab)

* U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) IN INTERMEDIATE- AND POOR-RISK PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AND GRANTS PRIORITY REVIEW

Select another date: